JP5085222B2 - B型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキサンケトン化合物 - Google Patents
B型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキサンケトン化合物 Download PDFInfo
- Publication number
- JP5085222B2 JP5085222B2 JP2007203975A JP2007203975A JP5085222B2 JP 5085222 B2 JP5085222 B2 JP 5085222B2 JP 2007203975 A JP2007203975 A JP 2007203975A JP 2007203975 A JP2007203975 A JP 2007203975A JP 5085222 B2 JP5085222 B2 JP 5085222B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- virus
- pharmaceutical composition
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/02—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains containing only carbon and hydrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
[引用文献2]Chen, C. H., and Yang, S. W. 1995. New steroid acids from Antrodia cinnamomea, −a fungus parasitic on Cinnamomum micranthum. J. Nat. Prod. 58:1655−1661
[引用文献3]Chiang, H. C., Wu, D. P., Cherng, I. W., and Ueng, C. H. 1995. A sesquiterpene lactone, phenyl and biphenyl compounds from Antrodia cinnamomea. Phytochemistry. 39:613−616
[引用文献4]Cherng, I. H., Wu, D. P., and Chiang, H. C. 1996. Triteroenoids from Antrodia cinnamomea. Phytochemistry. 41:263−267
[引用文献5]Yang, S. W., Shen, Y. C., and Chen, C. H. 1996. Steroids and triterpenoids of Antrodia cinnamomea−a fungus parasitic on Cinnamomum micranthum. Phytochemistry. 41:1389−1392
内、Xは酸素(O)或いはイオウ(S)で、Yは酸素(O)或いはイオウ(S)で、R1は水素(H)、メチル(CH3)或いは(CH2)m−CH3で、R2は水素、メチル或いは(CH2)m−CH3で、R3は水素、メチル或いは(CH2)m−CH3,m=1〜12で、n=1〜12である。
請求項2の発明は、前記化合物はベニクスノキタケの有機溶剤抽出物中から分離製造することを特徴とする請求項1記載のB型肝炎ウィルスの抑制に用いるベニクスノキタケのシクロヘキセンケトン抽出物としている。
請求項3の発明は、前記有機溶剤はエステル類、アルコール類、アルケン類或いはハロセンにより組成するグループから選択することを特徴とする請求項2記載のB型肝炎ウィルスの抑制に用いるベニクスノキタケのシクロヘキセンケトン抽出物としている。
請求項4の発明は、前記アルコール類はエタノールであることを特徴とする請求項3記載のB型肝炎ウィルスの抑制に用いるベニクスノキタケのシクロヘキセンケトン抽出物としている。
請求項5の発明は、前記化合物はベニクスノキタケの水抽出物中より分離製造することを特徴とする請求項1記載のB型肝炎ウィルスの抑制に用いるベニクスノキタケのシクロヘキセンケトン抽出物としている。
請求項6の発明は、前記化合物は4-ハイドロキシ-2,3-ジメトキシ-6-メチル-5(3,7,11-トリメチル-ドデカ-2,6,10-トリエニル)-シクロヘキセ-2-エンオン(4−hydroxy−2,3−dimethoxy−6−methyl−5(3,7,11− trimethyl−dodeca−2,6,10−trienyl)−cyclohex−2−enone)であることを特徴とする請求項1記載のB型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキセンケトン化合物としている。
請求項7の発明は、前記化合物はB型肝炎表面抗原(HbsAg)及びB型肝炎エンベロープ抗原(HbeAg)の生成量を低下させることによりB型肝炎ウィルスを抑制することを特徴とする請求項1或いは請求項6記載のB型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキセンケトン化合物としている。
請求項8の発明は、前記化合物がB型肝炎表面抗原(HbsAg)生成量を低下させる最適使用濃度は10μg/mlであることを特徴とする請求項7記載のB型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキセンケトン化合物としている。
請求項9の発明は、前記化合物がB型肝炎エンベロープ抗原(HbeAg)生成量を低下させる最適使用濃度は1μg/mlであることを特徴とする請求項7記載のB型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキセンケトン化合物としている。
請求項10の発明は、B型肝炎ウィルスが引き起こす疾病の治療に用いる医薬組成物は少なくとも有効剤量の請求項1記載の化合物と医学上受け入れ可能なキャリアを含むことを特徴とするB型肝炎ウィルスが引き起こす疾病の治療に用いる医薬組成物としている。
請求項11の発明は、B型肝炎ウィルスが引き起こす疾病の治療に用いる医薬組成物は少なくとも有効剤量の請求項6記載の化合物と医学上受け入れ可能なキャリアを含むことを特徴とするB型肝炎ウィルスが引き起こす疾病の治療に用いる医薬組成物としている。
請求項12の発明は、前記B型肝炎ウィルスが引き起こす疾病は急性肝炎、慢性肝炎、肝硬変、肝臓癌を含むことを特徴とする請求項10或いは請求項11記載のB型肝炎ウィルスが引き起こす疾病の治療に用いる医薬組成物としている。
前記実施方式に対して以下に詳細に説明する。
Claims (12)
- 以下の構造式で表される化合物
- 前記化合物はベニクスノキタケの有機溶剤抽出物中から分離製造することを特徴とする請求項1記載の医薬組成物。
- 前記有機溶剤はメタノール、エタノール、プロパノール、アセチジン、ヘキサン、クロロメタン、エチルクロライドからなるグループから選択することを特徴とする請求項2記載の医薬組成物。
- 前記有機溶媒はエタノールであることを特徴とする請求項3記載の医薬組成物。
- 前記化合物はベニクスノキタケの水抽出物中より分離製造することを特徴とする請求項1記載の医薬組成物。
- 前記化合物は4-ハイドロキシ-2,3-ジメトキシ-6-メチル-5(3,7,11-トリメチル-ドデカ-2,6,10-トリエニル)-シクロヘキセ-2-エンオン(4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11- trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone)であることを特徴とする請求項1〜5のいずれか1項に記載の医薬組成物。
- 前記化合物はB型肝炎表面抗原(HbsAg)及び/又はB型肝炎エンベロープ抗原(HbeAg)の生成量を低下させることによりB型肝炎ウィルスを抑制することを特徴とする請求項1〜6のいずれか1項に記載の医薬組成物。
- 前記化合物がB型肝炎表面抗原(HbsAg)生成量を低下させるのに適した濃度は10μg/mlであることを特徴とする請求項7記載の医薬組成物。
- 前記化合物がB型肝炎エンベロープ抗原(HbeAg)生成量を低下させるのに適した濃度は1μg/mlであることを特徴とする請求項7記載の医薬組成物。
- 請求項1に定義された化合物と医学上受け入れ可能なキャリアを含むことを特徴とするB型肝炎ウィルスが引き起こす疾病の治療に用いる医薬組成物。
- 請求項6に定義された化合物と医学上受け入れ可能なキャリアを含むことを特徴とするB型肝炎ウィルスが引き起こす疾病の治療に用いる医薬組成物。
- 前記B型肝炎ウィルスが引き起こす疾病は急性肝炎、慢性肝炎、肝硬変、または肝臓癌であることを特徴とする請求項10または11記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW096124892 | 2007-07-09 | ||
TW096124892A TWI394575B (zh) | 2007-07-09 | 2007-07-09 | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009013152A JP2009013152A (ja) | 2009-01-22 |
JP5085222B2 true JP5085222B2 (ja) | 2012-11-28 |
Family
ID=39048358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007203975A Active JP5085222B2 (ja) | 2007-07-09 | 2007-08-06 | B型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキサンケトン化合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7411003B1 (ja) |
JP (1) | JP5085222B2 (ja) |
KR (1) | KR101218510B1 (ja) |
DE (1) | DE102007043187A1 (ja) |
FR (1) | FR2918663A1 (ja) |
GB (1) | GB2450949B (ja) |
TW (1) | TWI394575B (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI394573B (zh) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
TWI394575B (zh) * | 2007-07-09 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus |
JP5203644B2 (ja) * | 2007-07-13 | 2013-06-05 | 國鼎生物科技股▲ふん▼有限公司 | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 |
EP2329816B1 (en) | 2009-11-26 | 2016-04-13 | National Taiwan University | An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof |
JP2012012343A (ja) * | 2010-07-01 | 2012-01-19 | Taiwan Leader Biotech Corp | 肝炎を治療するための医薬組成物及びその用途 |
TW201231474A (en) * | 2011-01-26 | 2012-08-01 | Univ Kaohsiung Medical | Triterpenoid composition of Antrodia cinnamomea, preparation and analysis method thereof |
CA2800329A1 (en) * | 2011-12-30 | 2013-06-30 | Golden Biotechnology Corporation | Methods and compositions for treating diabetes |
CN102603619B (zh) * | 2012-02-15 | 2013-09-18 | 合肥工业大学 | 一种具有抗癌活性的化合物及其制备方法 |
US9789153B2 (en) | 2014-07-02 | 2017-10-17 | Hsiu-Hsien Tsai | Composition for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs |
US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
ES2938341T3 (es) | 2016-03-07 | 2023-04-10 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis B |
SG11201810834WA (en) | 2016-06-10 | 2018-12-28 | Enanta Pharm Inc | Hepatitis b antiviral agents |
EA202090514A1 (ru) | 2017-08-28 | 2020-06-24 | Энанта Фармасьютикалс, Инк. | Противовирусное средство против гепатита в |
TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
KR20210093951A (ko) | 2018-11-21 | 2021-07-28 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서의 작용화된 헤테로사이클 |
JP2022523521A (ja) * | 2019-02-25 | 2022-04-25 | アージル・バイオテック・ホールディング・カンパニー・リミテッド | ウイルス感染を阻害するための方法および組成物 |
US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
CN115697313A (zh) * | 2020-05-08 | 2023-02-03 | 国鼎生物科技股份有限公司 | 用于治疗rna病毒诱导的疾病的方法和组合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3064012A (en) * | 1960-07-20 | 1962-11-13 | Merck & Co Inc | Derivatives of coenzyme q10 |
CN1386545A (zh) * | 2001-05-18 | 2002-12-25 | 葡萄王企业股份有限公司 | 樟芝保肝制剂 |
US6740517B2 (en) * | 2001-12-14 | 2004-05-25 | Ming-Huang Lan | Incubation method for obtaining solid culture of Zang Zhi, solid culture obtained therefrom, processed products and use thereof |
JP2004091780A (ja) * | 2002-08-30 | 2004-03-25 | Taiso Seibutsu Kagi Kofun Yugenkoshi | Antrodiacamphorata菌体の多糖類 |
JP5403844B2 (ja) * | 2004-03-02 | 2014-01-29 | 善笙生物科技股▲分▼有限公司 | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 |
KR20050091464A (ko) * | 2004-03-12 | 2005-09-15 | 심프슨 바이오테크 컴퍼니 리미티드 | 안트로디아 캄포라타 균사체 유래의 신규한 혼합물 및화합물, 및 그의 용도 |
US20060135623A1 (en) * | 2004-05-21 | 2006-06-22 | Cutler Richard G | Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs |
CN100394927C (zh) * | 2005-09-28 | 2008-06-18 | 莱阳农学院 | 一种抗肝癌的樟芝胶囊及其制备方法 |
CN100384982C (zh) * | 2005-09-28 | 2008-04-30 | 莱阳农学院 | 一种樟芝菌丝体发酵提取物及其应用 |
TW200829234A (en) * | 2007-01-08 | 2008-07-16 | Golden Biotechnology Corp | Antrodia camphorata isophorone extract |
CN101225066B (zh) * | 2007-01-18 | 2010-09-22 | 国鼎生物科技股份有限公司 | 牛樟芝的环己烯酮萃取物 |
TWI394572B (zh) * | 2007-06-12 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum aurantii Cyclohexenone Compounds in the Preparation of Drugs for the Treatment of Autoimmune Diseases |
TWI394575B (zh) * | 2007-07-09 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus |
-
2007
- 2007-07-09 TW TW096124892A patent/TWI394575B/zh active
- 2007-08-06 JP JP2007203975A patent/JP5085222B2/ja active Active
- 2007-08-21 US US11/842,795 patent/US7411003B1/en active Active
- 2007-08-28 KR KR1020070086411A patent/KR101218510B1/ko not_active IP Right Cessation
- 2007-09-11 DE DE102007043187A patent/DE102007043187A1/de not_active Withdrawn
- 2007-12-19 GB GB0724754.7A patent/GB2450949B/en not_active Expired - Fee Related
-
2008
- 2008-04-17 FR FR0802140A patent/FR2918663A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
TW200902041A (en) | 2009-01-16 |
KR20090005932A (ko) | 2009-01-14 |
JP2009013152A (ja) | 2009-01-22 |
GB0724754D0 (en) | 2008-01-30 |
TWI394575B (zh) | 2013-05-01 |
KR101218510B1 (ko) | 2013-01-03 |
GB2450949A (en) | 2009-01-14 |
GB2450949B (en) | 2012-04-11 |
FR2918663A1 (fr) | 2009-01-16 |
DE102007043187A1 (de) | 2009-01-15 |
US7411003B1 (en) | 2008-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5085222B2 (ja) | B型肝炎ウィルスの抑制に用いるベニクスノキタケシクロヘキサンケトン化合物 | |
JP5085186B2 (ja) | ベニクスノキタケから単離された新規化合物 | |
KR100897988B1 (ko) | 안트로디아 캄포라타로부터 얻은 신규 화합물 | |
KR101150046B1 (ko) | 자가면역 질병을 치료하기 위한 안트로디아 캄포라타로부터얻은 시클로헥세논 화합물 | |
KR101069959B1 (ko) | 안트로디아 캄포라타로부터 얻은 시클로헥세논 유형의 간보호 화합물 | |
RU2422431C2 (ru) | Новые циклогексеноновые соединения из антродии камфорной (antrodia camphorata) и их применение | |
WO2009052711A1 (fr) | Nouveaux composés isolés d'un extrait d'antrodia camphorata | |
EP2221291A1 (en) | Cyclohexenone compounds from antrodia camphorata and pharmaceutical compositions thereof useful for treating autoimmune diseases | |
TWI394566B (zh) | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds | |
TW201102075A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer | |
JP5019946B2 (ja) | ベニクスノキタケ抽出物化合物の腫瘍細胞生長抑制に対する応用 | |
JP5203644B2 (ja) | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 | |
CN101362679B (zh) | 用于抑制b型肝炎病毒的牛樟芝环己烯酮化合物 | |
TWI361687B (ja) | ||
WO2009026794A1 (fr) | Composés de cyclohexénone issus de antrodia camphorata destinés à la protection du foie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081225 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120409 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120409 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120814 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120905 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5085222 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150914 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |